Magle Chemoswed Holding Ab (MAGLE) - Total Assets
Based on the latest financial reports, Magle Chemoswed Holding Ab (MAGLE) holds total assets worth Skr1.04 Billion SEK (≈ $111.79 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See MAGLE book value for net asset value and shareholders' equity analysis.
Magle Chemoswed Holding Ab - Total Assets Trend (2017–2024)
This chart illustrates how Magle Chemoswed Holding Ab's total assets have evolved over time, based on quarterly financial data.
Magle Chemoswed Holding Ab - Asset Composition Analysis
Current Asset Composition (December 2024)
Magle Chemoswed Holding Ab's total assets of Skr1.04 Billion consist of 24.5% current assets and 75.5% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0.3% |
| Accounts Receivable | Skr131.40 Million | 12.0% |
| Inventory | Skr133.08 Million | 12.2% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr96.01 Million | 8.8% |
| Goodwill | Skr188.92 Million | 17.3% |
Asset Composition Trend (2017–2024)
This chart illustrates how Magle Chemoswed Holding Ab's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Magle Chemoswed Holding Ab.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Magle Chemoswed Holding Ab's current assets represent 24.5% of total assets in 2024, a decrease from 60.7% in 2017.
- Cash Position: Cash and equivalents constituted 0.3% of total assets in 2024, down from 9.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 25.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 17.3% of total assets.
Magle Chemoswed Holding Ab Competitors by Total Assets
Key competitors of Magle Chemoswed Holding Ab based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Magle Chemoswed Holding Ab - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.96 | 0.97 | 1.37 |
| Quick Ratio | 0.82 | 0.49 | 0.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr134.48 Million | Skr-7.18 Million | Skr17.40 Million |
Magle Chemoswed Holding Ab - Advanced Valuation Insights
This section examines the relationship between Magle Chemoswed Holding Ab's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.42 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 300.1% |
| Total Assets | Skr1.09 Billion |
| Market Capitalization | $10.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values Magle Chemoswed Holding Ab's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Magle Chemoswed Holding Ab's assets grew by 300.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Magle Chemoswed Holding Ab (2017–2024)
The table below shows the annual total assets of Magle Chemoswed Holding Ab from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr1.09 Billion ≈ $117.54 Million |
+300.11% |
| 2023-12-31 | Skr272.97 Million ≈ $29.38 Million |
+7.95% |
| 2022-12-31 | Skr252.86 Million ≈ $27.21 Million |
+6.61% |
| 2021-12-31 | Skr237.18 Million ≈ $25.52 Million |
+19.75% |
| 2020-12-31 | Skr198.06 Million ≈ $21.31 Million |
-6.70% |
| 2019-12-31 | Skr212.28 Million ≈ $22.84 Million |
+39.16% |
| 2018-12-31 | Skr152.54 Million ≈ $16.42 Million |
+3.15% |
| 2017-12-31 | Skr147.88 Million ≈ $15.91 Million |
-- |
About Magle Chemoswed Holding Ab
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride… Read more